RedHill Biopharma Ltd. provided earnings guidance for fourth quarter of 2021. For the quarter, the company record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21.6 million in Q3/2021 and $21.5 in Q4/2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4475 USD | -2.31% | -1.97% | -69.35% |
05-06 | Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib | MT |
05-06 | RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035 | CI |
1st Jan change | Capi. | |
---|---|---|
-69.35% | 14.6M | |
-1.85% | 89.87B | |
-1.05% | 37.57B | |
-11.20% | 32.75B | |
+61.85% | 26.47B | |
-20.75% | 14.25B | |
-6.35% | 12.99B | |
-11.42% | 11.93B | |
-47.67% | 10.84B | |
+5.99% | 9.11B |
- Stock Market
- Equities
- RDHL Stock
- News RedHill Biopharma Ltd.
- Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021